Curing chronic myeloid leukemia

Current Hematologic Malignancy Reports

Volumn 7, Issue 2, 2012, Pages 103-108

  Rea, Delphine ^a   Rousselot, Philippe ^b   Guilhot, Joelle ^c   Guilhot, François ^c   Mahon, François Xavier ^d  

^a SAINT LOUIS HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c UNIVERSITÉ DE POITIERS   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

BCR ABL1 . Chronic myeloid leukemia . Tyrosine kinase inhibitors . Leukemic stem cells . Cure

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CHRONICITY; CLINICAL TRIAL (TOPIC); DRUG SAFETY; HEALTH CARE COST; HUMAN; MINIMAL RESIDUAL DISEASE; NONHUMAN; PATIENT COMPLIANCE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84860839007     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0117-2     Document Type: Article

References (53)

1. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-? versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541-8.
2. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003, 348:994-1004. This study shows that imatinib is superior to previous treatment option interferon plus cytarabine as first-line therapy in patients with newly diagnosed CP-CML. (Pubitemid 36302244)
3. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108:1478-84. (Pubitemid 44316111)
4. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041-51.
5. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204-12.
6. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-6. (Pubitemid 350159618)
7. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Eng J Med. 2010;362:2260-70.
8. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia. New Eng J Med. 2010;362:2251-9.
9. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Blood (ASH annual Meeting Abstracts). 2011;118:109.
10. Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514-20.
11. Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma. 2006;47:1-7. (Pubitemid 43101717)
12. Van Rhee F, Szydlo RM, Hermans J, et al. Long term results after allogeneic transplantation for chronic myelogenous leukemia in chronic phase: a report from the chronic leukemia working party of the European group for blood and marrow transplantation. Bone Marrow Transplant. 1997;20:553-60. (Pubitemid 27464562)
13. Pavlu J, Szydlo R, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117:755-63.
14. Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCRABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 2006;107:4171-6. (Pubitemid 43726829)
15. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late", 18 months or more after transplantation. Blood. 2001;98:1701-7.
16. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2001;20:214-20.
17. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758-65.
18. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104:2204-5. (Pubitemid 39297882)
19. Mauro MJ, Druker BJ, Marziaz RT. Divergent clinical outcome in twp CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28S1:S71-3. (Pubitemid 38251502)
20. Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:979-81. (Pubitemid 41020302)
21. Guastafierro S, Falcone U, Celentano M, et al. Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR/ABL? A case report and areview of the literature. Leuk Res. 2009;33:1079-81.
22. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58-60. (Pubitemid 46053043)
23. Mahon FX, Rea D, Guilhot J, et al.: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre, Stop IMatinib (STIM) trial. Lancet Oncol. 2010, 11:1029-1035. STIM is the first large-scale clinical trial which has addressed the feasibility of imatinib discontinuation in patients with long-lasting undetectable BCR-ABL transcripts.
24. Ross DM, Branford S, Seymour JF, et al.: Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010, 24:1719-1724. This study shows that most patients with undetectable BCR-ABL transcripts on imatinib have detectable BCR-ABL DNA, even those who discontinue imatinib and do not need to resume therapy, suggesting that treatment discontinuation does not require leukemic cell eradication.
25. Rea D, Raffoux E, Cayuela JM, et al. Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia. Leukemia. 2009;23:1158-9.
26. Ross DM, Bartley PA, Goyne J, et al. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica. 2011;96:1720-2.
27. Rea D, Rousselot P, Nicolini FE, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia patients with stable undetectable Bcr-Abl transcripts: results from the French CML group (FILMC). Blood (ASH Annual Meeting Abstracts). 2011;118:604.
28. Chomel J-C, Bonnet M-L, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118:3657-60.
29. Mahon F-X, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study. Blood (ASH Annual Meeting Abstracts). 2011;118:603.
30. Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-7. (Pubitemid 28492345)
31. Hughes TP, Lipton JH, Leber B, et al. Complete molecular response (CMR) rate with nilotinib in patients with chronic myeloid leukemia in chronic phase without CMR ≥ 2 years on imatinib: preliminary results from the randomized ENESTcmr trial of nilotinib 400 mg twice daily (BID) vs imatinib. Blood (ASH Annual Meeting Abstracts). 2011;118:606.
32. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565-72.
33. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-25.
34. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532-9. (Pubitemid 43801382)
35. Jorgensen HG, Allan EK, Jordanides NE, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007;109:4016-9. (Pubitemid 46641755)
36. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396-409.
37. Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501-10.
38. Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol. 2010;80:602-12.
39. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591-9.
40. Lemoli RM, Salvestrini V, Bianchi E, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood. 2009;114:5191-200.
41. Chen Y, Peng C, Sullivan C, et al. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia. 2010;24:1545-54.
42. Chomel J-C, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011;2:713-27.
43. Hegde S, Kaushal N, Ravindra KC, et al. ?12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells inmice. Blood. 2011;118:6909-19.
44. Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci. 2010;101:1577-81.
45. Cilloni D, Saglio G: Molecular pathways: BCR-ABL. Clin Cancer Res Published OnlineFirst December 8, 2011; doi:10.1158/1078-0432.CCR-10-1613.
46. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicenter observational trial. Lancet. 2005;365:657-62. (Pubitemid 40260886)
47. Drummond MW, Heaney N, Kaeda J, et al. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia. 2009;23:1199-201.
48. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009;119:1109-23.
49. Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol. 2010;28:5321-6.
50. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. New Engl J Med. 2010;363:2511-21.
51. Sato T, Onai N, Yishihara H, et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferondependent exhaustion. Nat Med. 2009;15:696-700.
52. Essers MAG, Offner S, Blanco-Bose WE, et al. IFN? activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904-8.
53. Bhattacharya S, Zheng H, Tzimas C, et al. Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFN? via accelerating the degradation of its receptor. Blood. 2011;118:4179-87.